Nivolumab: tested in a combination
680 studies: another drug in the study is under test too. Page 2 of 7. Open to participants first (135), then studies with results posted, then the rest; newest registration first within each.
- A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain MetastasesRecruitingNCT05048212Phase 2Report a problem
- Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint InhibitorsRecruitingNCT05039073Phase 2Report a problem
- Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ AdenocarcinomaRecruitingNCT04997837Phase 3Report a problem
- Using ctDNA to Determine Therapies for Lung CancerRecruitingNCT04966663Phase 2Report a problem
- BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and NivolumabRecruitingNCT04933903Phase 2Report a problem
- Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIVRecruitingNCT04902443Phase 1Report a problem
- An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)RecruitingNCT04876313Phase 2Report a problem
- Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular CarcinomaRecruitingNCT04823403Phase 1Report a problem
- Intra-tumor Injection of Drug-eluting Microspheres With Multiple DrugsRecruitingNCT04770207Phase 2Report a problem
- PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapyRecruitingNCT04745949Phase 2Report a problem
- Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare SubtypeRecruitingNCT04741438Phase 3Report a problem
- Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin LymphomaRecruitingNCT04561206Phase 2Report a problem
- A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingNCT04546399Phase 2Report a problem
- GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced SarcomaRecruitingNCT04535713Phase 2Report a problem
- Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular CarcinomaRecruitingNCT04472767Phase 2Report a problem
- Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic CancersRecruitingNCT04295863Phase 1Report a problem
- Nivolumab for Treatment of Squamous Cell Carcinoma of the SkinRecruitingNCT04204837Phase 2Report a problem
- Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric AdenocarcinomaRecruitingNCT04150640Phase 2Report a problem
- Pan Tumor Rollover StudyRecruitingNCT03899155Phase 2Report a problem
- Talimogene Laherparepvec, Nivolumab and Trabectedin for SarcomaRecruitingNCT03886311Phase 2Report a problem
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingNCT03866382Phase 2Report a problem
- A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI StudyRecruitingNCT03844256Phase 1/2Report a problem
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVORecruitingNCT03816345Phase 1Report a problem
- Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IORecruitingNCT03815890Phase 2Report a problem
- Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin LymphomaRecruitingNCT03681561Phase 1/2Report a problem
- Melanoma Metastasized to the Brain and SteroidsRecruitingNCT03563729Phase 2Report a problem
- Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell CarcinomaRecruitingNCT03521830Phase 2Report a problem
- Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell CarcinomaRecruitingNCT03406247Phase 2Report a problem
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingNCT03297606Phase 2Report a problem
- Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma PatientsRecruitingNCT03166397Phase 2Report a problem
- SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue SarcomaRecruitingNCT03138161Phase 1/2Report a problem
- Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon CancerRecruitingNCT03026140Phase 2Report a problem
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2Report a problem
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingNCT02813135Phase 1/2Report a problem
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingNCT02693535Phase 2Report a problem
- A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose CombinationsActive, not recruitingNCT06101134Phase 2Results postedReport a problem
- Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant CholangiocarcinomaTerminatedNCT05921760Phase 1/2Results postedReport a problem
- A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable MelanomaActive, not recruitingNCT05625399Phase 3Results postedReport a problem
- A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal CancerTerminatedNCT05328908Phase 3Results postedReport a problem
- A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin LymphomaTerminatedNCT05255601Phase 1/2Results postedReport a problem
- Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous MelanomaTerminatedNCT05200143Phase 2Results postedReport a problem
- A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal MesotheliomaCompletedNCT05041062Phase 2Results postedReport a problem
- Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHLActive, not recruitingNCT04938232Phase 2Results postedReport a problem
- RegoNivo vs Standard of Care Chemotherapy in AGOCCompletedNCT04879368Phase 3Results postedReport a problem
- A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid TumorsCompletedNCT04704154Phase 2Results postedReport a problem
- Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable MelanomaTerminatedNCT04688658Phase 1/2Results postedReport a problem
- Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose IpilimumaTerminatedNCT04655157Phase 1/2Results postedReport a problem
- Trying to Find the Correct Length of Treatment With Immune Checkpoint TherapyActive, not recruitingNCT04637594Phase 3Results postedReport a problem
- A Study of Rucaparib and Nivolumab in People With LeiomyosarcomaActive, not recruitingNCT04624178Phase 2Results postedReport a problem
- Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVActive, not recruitingNCT04514484Phase 1Results postedReport a problem
- A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in IndiaCompletedNCT04513522Phase 4Results postedReport a problem
- Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced MelanomaCompletedNCT04493203Phase 2Results postedReport a problem
- Neoadjuvant Immunotherapy in Brain MetastasesTerminatedNCT04434560Phase 2Results postedReport a problem
- Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative CancersActive, not recruitingNCT04416568Phase 2Results postedReport a problem
- Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated GlioblastomaCompletedNCT04396860Phase 2/3Results postedReport a problem
- A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver CancerCompletedNCT04340193Phase 3Results postedReport a problem
- Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue SarcomaActive, not recruitingNCT04339738Phase 2Results postedReport a problem
- Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior ImmunotherapyCompletedNCT04326257Phase 2Results postedReport a problem
- Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial CarcinomaTerminatedNCT04322643Phase 2Results postedReport a problem
- Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)CompletedNCT04282109Phase 2Results postedReport a problem
- Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid LeukemiaCompletedNCT04277442Phase 1Results postedReport a problem
- A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder CancerCompletedNCT04209114Phase 3Results postedReport a problem
- Cabozantinib and Nivolumab for Carcinoid TumorsCompletedNCT04197310Phase 2Results postedReport a problem
- Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness GenesCompletedNCT04187833Phase 2Results postedReport a problem
- Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)CompletedNCT04126733Phase 2Results postedReport a problem
- Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed TumorsActive, not recruitingNCT04126070Phase 2Results postedReport a problem
- Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory MyelomaTerminatedNCT04119336Phase 2Results postedReport a problem
- Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue SarcomaCompletedNCT04118166Phase 2Results postedReport a problem
- Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced MelanomaActive, not recruitingNCT04091750Phase 2Results postedReport a problem
- A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell CarcinomaTerminatedNCT04088500Phase 2Results postedReport a problem
- Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine TumorsActive, not recruitingNCT04079712Phase 2Results postedReport a problem
- Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant TumorsCompletedNCT04056910Phase 2Results postedReport a problem
- A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by SurgeryCompletedNCT04026412Phase 3Results postedReport a problem
- A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)Active, not recruitingNCT04008030Phase 3Results postedReport a problem
- A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV MelanomaActive, not recruitingNCT03999749Phase 2Results postedReport a problem
- High Dose IL-2 in Combination With Anti-PD-1TerminatedNCT03991130Phase 2Results postedReport a problem
- Combination Rucaparib With Nivolumab in Small Cell Lung CarcinomaCompletedNCT03958045Phase 2Results postedReport a problem
- De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal CancerActive, not recruitingNCT03952585Phase 2/3Results postedReport a problem
- De-Escalation Therapy for Human Papillomavirus Negative DiseaseCompletedNCT03944915Phase 2Results postedReport a problem
- Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid CancerActive, not recruitingNCT03914300Phase 2Results postedReport a problem
- Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin LymphomaActive, not recruitingNCT03907488Phase 3Results postedReport a problem
- Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain MetastasisTerminatedNCT03903640Phase 2Results postedReport a problem
- Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and NeckTerminatedNCT03854032Phase 2Results postedReport a problem
- Radiation and Combination Immunotherapy for MelanomaCompletedNCT03850691Phase 2Results postedReport a problem
- Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck CancerCompletedNCT03829722Phase 2Results postedReport a problem
- A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)TerminatedNCT03824704Phase 2Results postedReport a problem
- Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic CancersActive, not recruitingNCT03816332Phase 1Results postedReport a problem
- Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal CancerCompletedNCT03800602Phase 2Results postedReport a problem
- Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell CarcinomaTerminatedNCT03799445Phase 2Results postedReport a problem
- NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast CancerActive, not recruitingNCT03789110Phase 2Results postedReport a problem
- Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract CancerCompletedNCT03785873Phase 1/2Results postedReport a problem
- Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic CancersTerminatedNCT03785210Phase 2Results postedReport a problem
- Abemaciclib and Nivolumab for Subjects With Hepatocellular CarcinomaTerminatedNCT03781960Phase 2Results postedReport a problem
- Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland CancersCompletedNCT03749460Phase 1/2Results postedReport a problem
- Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic SettingCompletedNCT03743766Phase 2Results postedReport a problem
- Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT03739619Phase 1/2Results postedReport a problem
- Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin LymphomaActive, not recruitingNCT03712202Phase 2Results postedReport a problem
- Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal CancerCompletedNCT03711058Phase 1/2Results postedReport a problem
- Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal TumorsTerminatedNCT03693846Phase 2Results postedReport a problem
- Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular CarcinomaCompletedNCT03682276Phase 1/2Results postedReport a problem